Statin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ischemic Stroke
Conditions
Ischemic Stroke
Trial Timeline
Sep 1, 2015 → Mar 1, 2017
NCT ID
NCT02549846About Statin
Statin is a approved stage product being developed by Shionogi for Ischemic Stroke. The current trial status is completed. This product is registered under clinical trial identifier NCT02549846. Target conditions include Ischemic Stroke.
What happened to similar drugs?
9 of 13 similar drugs in Ischemic Stroke were approved
Approved (9) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02549846 | Approved | Completed |
Competing Products
20 competing products in Ischemic Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 26 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 32 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 29 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 26 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 35 |
| Regadenoson | Astellas Pharma | Phase 1 | 29 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 35 |
| Regadenoson | Astellas Pharma | Approved | 43 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 39 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 38 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 31 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 39 |
| fospropofol + propofol | Eisai | Phase 2 | 35 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 26 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 35 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 42 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Balovaptan + Placebo | Roche | Phase 2 | 27 |
| Repatha | Amgen | Approved | 35 |
| GS-6615 + Placebo | Gilead Sciences | Phase 1 | 29 |